Mylan has been backed by the European Medicines Agency’s Committee for Medicinal Products for Human Use to receive a pan-European marketing authorization for the US firm’s generic to Celgene’s Revlimid (lenalidomide) capsules to treat multiple myeloma and follicular lymphoma.
Announcing its recommendation for Lenalidomide Mylan, the CHMP said studies demonstrated “the satisfactory quality of Lenalidomide Mylan and its bioequivalence...